Aspirin Therapy in Diabetic Patients

Introduction to Aspirin Therapy

The American Diabetes Association recommends aspirin therapy for diabetic patients with established atherosclerotic cardiovascular disease (ASCVD) at 75-162 mg daily for secondary prevention 1
Aspirin therapy may be considered for primary prevention in diabetics aged 50-70 years with at least one additional major cardiovascular risk factor and low bleeding risk, after shared decision-making 1

The American College of Cardiology recommends using aspirin 75-162 mg daily indefinitely for any diabetic with prior myocardial infarction, stroke, transient ischemic attack, or documented ASCVD 1, 2
The cardiovascular mortality and morbidity reduction far outweighs bleeding risk in secondary prevention 1
For documented aspirin allergy, the American Heart Association recommends substituting clopidogrel 75 mg daily 1, 3
After acute coronary syndrome, dual antiplatelet therapy (aspirin plus P2Y12 inhibitor like ticagrelor or clopidogrel) should continue for at least 1 year, with duration determined by an interprofessional team 1, 4

The American Diabetes Association recommends considering aspirin 75-162 mg daily if the patient has ≥1 additional major risk factor: family history of premature ASCVD, hypertension, dyslipidemia, smoking, or chronic kidney disease/albuminuria 1, 5
This recommendation requires comprehensive shared decision-making, as cardiovascular events prevented approximately equal bleeding episodes induced 1
The ASCEND trial demonstrated that over 7.4 years, serious vascular events occurred in 8.5% with aspirin versus 9.6% with placebo (12% reduction), but major bleeding increased from 3.2% to 4.1% 1

The American College of Cardiology recommends using 75-162 mg daily, with 81 mg being the most common U.S. formulation 1, 2
The ADAPTABLE trial found no difference in cardiovascular events or bleeding between 81 mg and 325 mg daily in patients with established cardiovascular disease 4
Lower doses (75-81 mg) minimize gastrointestinal bleeding while maintaining efficacy 2, 3

The American Heart Association recommends actively excluding high bleeding risk factors, including age >70 years, history of gastrointestinal ulcers or bleeding, anemia or bleeding disorders, chronic kidney disease, and concurrent use of NSAIDs, anticoagulants, or corticosteroids 1, 3

The American College of Cardiology recommends considering aspirin plus low-dose rivaroxaban to prevent major adverse limb and cardiovascular events in stable coronary or peripheral artery disease with low bleeding risk 1
Coronary calcium scoring may help refine risk stratification in borderline cases 1